Co-treatment with BEZ235 Enhances Sensitivity of BRCA1-negative Breast Cancer Cells to Olaparib | Anticancer Research
Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas - Gynecologic Oncology
A) Dose-response curves of compound 1-3 and olaparib for PARP-1... | Download Scientific Diagram
RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer | Science Advances
Dual mechanism of action of PARPi. Notes: Olaparib inhibits parylation... | Download Scientific Diagram
Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells | Nature Communications
Inhibitors of PARP: Number crunching and structure gazing | PNAS
Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer | PLOS ONE
An Overview of PARP Inhibitors for the Treatment of Breast Cancer | SpringerLink
The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: A potential opportunity for repurposing a
PARP Inhibitors in Maintenance Treatment for Advanced Ovarian Cancer - The ASCO Post
The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma | Journal of Experimental & Clinical Cancer Research | Full Text
A decade of clinical development of PARP inhibitors in perspective - Annals of Oncology
NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression | Nature Communications
Role of PARP Inhibitors in BRCA-Related Malignancies
An Overview of PARP Inhibitors for the Treatment of Breast Cancer | SpringerLink
Missense mutations interfere with PARP1 DNA binding. (a) Olaparib... | Download Scientific Diagram
Olaparib Maintenance Therapy Delays Ovarian Cancer Progression - NCI
Frontiers | PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
What Is LYNPARZA® (olaparib)?
Olaparib オラパリブ 奥拉帕尼 (AZD-2281, trade name Lynparza) AZ' first-in-class PARP inhibitor wins EU nod | New Drug Approvals
Parp Inhibitor Olaparib (Selleck Chemicals) | Bioz | Ratings For Life-Science Research
Nausea and Vomiting: Managing Side Effects From PARP Inhibitors
PARP Inhibition Restores Extrinsic Apoptotic Sensitivity in Glioblastoma | PLOS ONE
Integration of PARP-inhibitors in ovarian cancer therapy
Nausea and Vomiting: Managing Side Effects From PARP Inhibitors
